Introduction: We compared the disease free-survival (DFS) and overall survival (OS) rates of patients with high-grade serous primary fallopian tube cancer (HG-sPFTC) and high-grade serous epithelial ovarian cancer (HG-sEOC). Methods: 22 early-stage cancer patients (International Federation of Gynecology and Obstetrics (FIGO) stages I-II) with HG-sPFTC were retrospectively evaluated. In addition, 44 control patients diagnosed with HG-sEOC were matched to these patients with respect to tumor stage at diagnosis. All patients underwent complete surgical staging, followed by adjuvant chemotherapy. Kaplan-Meier curves were used to generate survival data. Results: The mean age of HG-sPFTC patients was 59.4 ± 6.2 years, and that of HG-sEOC patients 55.2 ± 11.0 years (p = 0.002). All patients underwent 6 cycles of platinum-based adjuvant chemotherapy. All operations were optimal. The 5-year DFSs were 77.3% for HG-sPFTC patients and 75% for HG-sEOC patients (p = 1.00).The 5-year OS rates were 81.8% in women with HG-sPFTC and 77.3% in those with HG-sEOC (p = 0.75). Conclusion: The DFS and OS rates of patients with early-stage (FIGO stages I and II) HG-sPFTC and HG-sEOC were similar. The surgical and adjuvant therapy management of these malignancies should be similar.

Journal Section:
Original Article
Keywords:
Primary fallopian tube cancer, Epithelial ovarian cancer, High-grade serous cancer
1.
Nezhat FR, Apostol R, Nezhat C, Pejovic T: New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. Am J Obstet Gynecol 2015;213:262-267.
2.
Dubeau L: The cell of origin of ovarian epithelial tumours. Lancet Oncol 2008;9:1191-1197.
3.
Kalampokas E, Kalampokas T, Tourountous I: Primary fallopian tube carcinoma. Eur J Obstet Gynecol Reprod Biol 2013;169:155-161.
4.
Moore KN, Moxley KM, Fader AN, et al.: Serous fallopian tube carcinoma: A retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary. Gynecol Oncol 2007;107:398-403.
5.
Wethington SL, Herzog TJ, Seshan VE, et al.: Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer. Cancer 2008;113:3298-306.
6.
Vaysse C, Touboul C, Filleron T, et al.: Early stage (IA-IB) primary carcinoma of the fallopian tube: Case-control comparison to adenocarcinoma of the ovary. J Gynecol Oncol 2011;22:9-17.
7.
Horng HC, Lai CR, Chang WH, et al.: Comparison of early-stage primary serous fallopian tube carcinomas and equivalent stage serous epithelial ovarian carcinomas. Taiwan J Obstet Gynecol 2014;53:547-551.
8.
Rauh-Hain JA, Foley OW, Winograd D, et al.: Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer. Am J Obstet Gynecol 2015;212:600.e1-8.
9.
Rosen AC, Sevelda P, Klein M, et al.: A comparative analysis of management and prognosis in stage I and II fallopian tube carcinoma and epithelial ovarian cancer. Br J Cancer 1994;69:577-579.
10.
Hu CY, Taymor ML, Hertig AT: Primary carcinoma of the fallopian tube. Am J Obstet Gynecol 1950;59:58-67.
11.
Sedlis A: Carcinoma of the fallopian tube. Surg Clin North Am 1978;58:121-129.
12.
Horng HC, Teng SW, Huang BS, et al.: Primary fallopian tube cancer: Domestic data and up-to-date review. Taiwan J Obstet Gynecol 2014;53:287-292.
© 2017 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.